Literature DB >> 16504613

Bisphosphonate actions: physical chemistry revisited.

Socrates E Papapoulos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16504613     DOI： 10.1016/j.bone.2006.01.141

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


× No keyword cloud information.
  13 in total

Review 1.  Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

Authors:  S E Papapoulos; R C Schimmer
Journal:  Ann Rheum Dis       Date:  2007-02-02       Impact factor: 19.103

Review 2.  Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds.

Authors:  Viviana Mouriño; Aldo R Boccaccini
Journal:  J R Soc Interface       Date:  2009-10-28       Impact factor: 4.118

3.  Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2011-05-21       Impact factor: 3.850

Review 4.  Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.

Authors:  Juan Pablo Cattalini; Aldo R Boccaccini; Silvia Lucangioli; Viviana Mouriño
Journal:  Tissue Eng Part B Rev       Date:  2012-05-14       Impact factor: 6.389

Review 5.  Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.

Authors:  Evangelos Terpos; Cyrille B Confavreux; Philippe Clézardin
Journal:  Bonekey Rep       Date:  2015-10-07

Review 6.  Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.

Authors:  Yusuf Farouk Suleman; Shabnum Meer; Russel Lurie
Journal:  Head Neck Pathol       Date:  2007-12-08

7.  Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.

Authors:  Amel Dudakovic; Emily T Camilleri; Fuhua Xu; Scott M Riester; Meghan E McGee-Lawrence; Elizabeth W Bradley; Christopher R Paradise; Eric A Lewallen; Roman Thaler; David R Deyle; A Noelle Larson; David G Lewallen; Allan B Dietz; Gary S Stein; Martin A Montecino; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2015-09-30       Impact factor: 5.157

8.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

Review 9.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

10.  Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.

Authors:  Robyn K Fuchs; Roger J Phipps; David B Burr
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.